CCA
SLXNW

Cobblestone Capital Advisors’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Cobblestone Capital Advisors’s Portfolio SLXNW Stock Details SLXNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$352 Hold
10,000
– – ﹤0.01% 304
2025
Q2 		$409 Hold
10,000
– – ﹤0.01% 302
2025
Q1 		$765 Hold
10,000
– – ﹤0.01% 293
2024
Q4 		$339 Hold
10,000
– – ﹤0.01% 294
2024
Q3 		$315 Buy
+10,000
New +$579 ﹤0.01% 287

Other funds holding SLXNW

OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
SBLIC
Security Benefit Life Insurance Company Topeka, Kansas $190M AUM 31.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Cobblestone Capital Advisors's SLXNW Position: Q3 2025 in Review

Cobblestone Capital Advisors held its Silexion Therapeutics Warrant (SLXNW) position steady in Q3 2025 at 10,000 shares worth $352. The position accounts for ﹤0.01% of the portfolio, ranked #304.

Cobblestone Capital Advisors first reported a position in SLXNW in Q3 2024 and has held it in 5 quarters since. The position peaked at $765 in Q1 2025. 22 funds tracked by Wall St. Rank hold SLXNW as of Q3 2025.

  • Cobblestone Capital Advisors held 10,000 shares of Silexion Therapeutics Warrant worth $352 as of Q3 2025.
  • Cobblestone Capital Advisors left its Silexion Therapeutics Warrant share count unchanged in Q3 2025.
  • Silexion Therapeutics Warrant made up ﹤0.01% of Cobblestone Capital Advisors's portfolio in Q3 2025, its #304 holding.
  • Cobblestone Capital Advisors first reported a position in Silexion Therapeutics Warrant in Q3 2024 and has held it in 5 quarters since.
  • Cobblestone Capital Advisors's Silexion Therapeutics Warrant position peaked at $765 in Q1 2025.
  • 22 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q3 2025.

Based on Cobblestone Capital Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.